Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beyond Victoza: Novo Nordisk Sheds Light On GLP-1/Insulin Product

This article was originally published in The Pink Sheet Daily

Executive Summary

Diabetes drug maker Novo Nordisk reports strong second quarter results based on its GLP-1 product, but could be facing some problems with other drugs in the pipeline.

You may also be interested in...



Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy

An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.

Degludec Advisory Committee Is Another De Facto Delay For Novo

FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.

In A Changing Diabetes Drug Market, Who Will Come Out On Top?

New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel